arrow
E

Espen A. Haavardsholm

Diakonhjemmet Hospital
H指数:47
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The association between systemic inflammation as measured by calprotectin and autoantibody load in rheumatoid arthritis

通过钙卫蛋白测量的系统性炎症与类风湿关节炎中自身抗体负荷的关联

2026-10-030
OAAI
Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial

Certolizumab pegol、abatacept、tocilizumab或早期类风湿关节炎的活性常规疗法:NORD-STAR试验的48周患者报告结局

2026-03-230
PRE
A DNA methylation-based algorithm for diagnosing rheumatoid arthritis

一种基于DNA甲基化的类风湿关节炎诊断算法

2025-10-190
OAAI
Correction: Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort

更正:早期类风湿关节炎的疾病活动度和治疗反应:NORD-STAR队列的一项探索性代谢组学分析

2025-10-030
OA
Acylcarnitine enrichment as a characteristic of rheumatoid arthritis fibroblast-like synoviocyte metabolic fingerprint

酰基肉碱富集作为类风湿关节炎成纤维样滑膜细胞代谢指纹的特征

2025-08-190
OAAI
Recognition of Glycine Versus Nonglycine Citrulline Motifs Dictating the HLA Class II Association of Anticitrullinated Protein Antibodies: Insights From Autoantibody Profiling of 6,900 Scandinavian Patients With Rheumatoid Arthritis

识别甘氨酸与瓜氨酸基序对决定抗瓜氨酸蛋白抗体与HLA II类分子结合的影响:来自对6,900名斯堪的纳维亚类风湿关节炎患者自身抗体谱分析的研究启示

2025-04-300
OAAI
Development of machine learning models for predicting non-remission in early RA highlights the robust predictive importance of the RAID score-evidence from the ARCTIC study

用于预测早期RA未缓解的机器学习模型的开发突出了RAID评分的强大预测重要性-来自北极研究的证据

2025-02-120
OAAI
SAFETY OF UPDATED XBB.1.5 SARS-CoV-2 VACCINE BOOSTERS IN PATIENTS WITH INFLAMMATORY JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPIES

更新后的XBB.1.5 SARS-CoV-2疫苗加强针在炎症性关节疾病并接受免疫抑制治疗患者中的安全性

2024-06-010
PRE
3-YEAR RESULTS OF TAPERING TNFi TO WITHDRAWAL COMPARED TO STABLE TNFi AMONG RHEUMATOID ARTHRITIS PATIENTS IN SUSTAINED REMISSION: A MULTICENTER RANDOMIZED TRIAL

3年随访结果:在持续缓解的类风湿关节炎患者中,将TNFi剂量递减至停药与维持稳定TNFi剂量进行比较:一项多中心随机试验

2024-06-010
PRE
DURABILITY OF CELLULAR AND HUMORAL IMMUNITY FOLLOWING A FIFTH SARS-CoV-2 VACCINE IN PATIENTS WITH INFLAMMATORY JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPIES

第五剂SARS-CoV-2疫苗在服用免疫抑制疗法的炎症性关节疾病患者中细胞免疫和体液免疫的持久性

2024-06-010
PRE
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial
2024-05-011
PRE
Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial
2024-01-182
OAAI
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
2023-02-266
OA
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
2023-01-0121
OAAI
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study
2022-10-0513
OAAI